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Summary.-Bilateral kidney ligation of mice immediately before injection of
misonidazole (MIS) prolongs the plasma half-life of this radiosensitizer from about
2 h (in normal mice) to 10-11 h, similar to that in man. Kidney ligation does not,
however, change the relative proportions of MIS and its 0-demethylated metabolite,
Ro-05-9963, for the first 12 h after MIS injection. Kidney ligation was used with the
two radiosensitizers, MIS and Ro-05-9963, to investigate the influence of plasma
half-life both on peak plasma levels and on the tumour/plasma ratio of sensitizer
concentration in the EMT6 mouse tumour.
Although the acute LD50 of Ro-05-9963 in normal mice was twice that of MIS.
this apparent advantage was offset by peak tumour levels 5000 or less of those
achieved by equimolar injected doses of MIS. However, by comparing the plasma and
tumour levels in mice in which the drug half-lives were prolonged by bilateral
kidney ligation, it was concluded that the lower plasma and tumour levels of Ro-05-
9963 were a result of its shorter plasma half-life, rather than of an intrinsic barrier
to tumour penetration. Because of this rapid clearance, the radiosensitization pro-
duced by Ro-05-9963 was less than that produced by equimolar injected doses of
MIS. As this difference did not occur in kidney-ligated mice, and hence would not
be expected to occur in man, the comparison of MIS and Ro-05-9963 in mice produces
an artificially low radiosensitization for Ro-05-9963 and possibly also for other
compounds with short plasma half-lives.
Although the short plasma half-life of Ro-05-9963 appeared to be responsible for
its low peak plasma concentration, it did not produce a low tumour/plasma ratio.
Within the limits of plasma nitroimidazole half-lives investigated (0-5-10 h) the
tumour/plasma ratio was insensitive to plasma half-life, being 50-70% for both MIS
and Ro-05-9963 in both normal and kidney-ligated mice. It is concluded that the
common assumption that tumour/plasma ratios of MIS in the mouse are less than
those in man is unjustified.
THE HYPOXIC CELL RADIOSENSITIZER
misonidazole (1-(2-nitroimidazol-1-yl)-3-
methoxypropan-2-ol, Ro-07-0582, MIS)
has been shown to be highly effective in
sensitizing hypoxic tumour cells (both
in vitro and in vivo) to cell killing by
radiation (Asquith et al., 1974; Denekamp
et al., 1974; Brown, 1975). There is also
evidence of radiosensitization of human
tumours by this drug (Thomlinson et al.,
1976). However, it is also apparent that
the neurological side effects of MIS limit
tumour levels of the drug to below
optimum values for radiosensitization
(Dische et al., 1977; Urtasun et al., 1978).
Indeed, if MIS were to be given in a
conventional fractionation regime, the
development of peripheral neuropathy
would limit plasma concentrations to
,20 ,tg/ml, for which sensitization-en-
hancement ratios of the hypoxic cells
would not be expected to be greater than
1L1 to 1-3.
Although it is possible that such a smallPHARMACOKINETICS OF HYPOXIC CELL RADIOSENSITIZERS
degree ofradiosensitization ofthe hypoxic
tumour cells could improve local control
for some tumours (owing to their steep
dose-response curves), it is clear that
MIS is not the "optimum" hypoxic cell
radiosensitizer for clinical application.
Such a radiosensitizer would be as effective
as MIS in its radio33nsitizing ability, but
only 1/10th as toxic. Several groups are
now pursuing such a goal (Adams, 1977;
Brown et al., 1978; Wardman, 1977).
It became apparent early in our studies
that the 0-demethylated metabolite
of MIS (1-(2-nitroimidazol-1-yl)-2,3-pro-
pandiol, Ro-05-9963) was less toxic in
mice, and hence might be a better drug
for clinical application. However, we also
found that Ro-05-9963 did not give as
high a level of radiosensitization of
tumours in vivo as MIS injected at
equimolar doses (Brown et al., 1978),
though this could be entirely explained by
lower tumour concentrations (Brown et al.,
in preparation). In order to determine
whether the lower tumour concentrations
of Ro-05-9963 than MIS are due to the
short plasma half-life of Ro-05-9963 in
the mouse, we have examined the in-
fluence of plasma half-life on tumour
concentration. Specifically the two ques-
tions were:
(a) How much does the plasma half-life
affect the peak plasma level?
(b) How much does the plasma half-life
affect the tumour/plasma ratio of
drug concentrations?
MATERIALS AND METHODS
A description of the procedures for implanta-
tion of tumours, and irradiation and assay
of the viability of the tumour cells has been
published previously (Brown, 1975). Brieflv,
the EMT6/St/lu tumour was transplanted
into 3-month-old, syngeneic BALB/c female
mice, weighing 20-25 g, and irradiated at a
diameter of 6-7 mm. Immediately after
irradiation the tumours were removed and
minced. The only modification was that the
single-cell suspensions were prepared by a
30 min disaggregation using an enzyme "'cock-
tail" of 0-05% pronase, 0.02% DNAase and
21
0 02% collagenase (Brown et al., in prepara-
tion). Cell viability was assayed by plating
appropriate dilutions of the tumour cells
into Waymouth's medium containing 15%
foetal calf serum in polystyrene Petri dishes,
and counting colonies 13 days later.
Both MIS (mol.wt 201) and Ro-05-9963
(mol.wt 187) were dissolved in physiological
saline or Hanks' medium immediately before
use, at a concentration sufficient to inject
the desired dose i.p. in 0 04-0 05 ml/g
body wt.
Bilateral kidney ligation was performed on
anaesthetized mice by exteriorizing the
kidneys through a 1 cm incision in the skin
and abdominal wall and tying a ligature
around the renal artery and vein at the renal
pelvis. The abdominal incision, which was
adjoining and parallel to the line of attach-
ment of the abdominal wall with the dorsal
muscles, was then closed tightly with 4 or 5
stitches, and the skin incision closed with
metal clips. The sham operation was identical
in all respects except for ligation of the renal
artery and vein. Mice were injected with MIS
or Ro-05-9963 when they had fully recovered
from the anaesthetic (,2 h after the opera-
tion).
Plasma (or whole blood) and tumour levels
of 2-nitroimidazoles were determined in
different ways in the two laboratories rep-
resented.
In the first method, represented in Tables
I and II and Fig. 1, tumour and plasma levels
were determined on killing of individual
mice, and were measured spectrophotomet-
rically using UV absorption at 318 nm. This
measures the total concentration of all
2-nitroimidazoles in the sample. The pro-
cedure used was a modification of that
described by Chapman et al. (1974). To
measure plasma levels, 0 4 ml of plasma
(collected from heparinized whole blood by
cardiac puncture at the time of killing) was
added to 2-6 nil absolute ethanol. The mixture
was vortexed for 1 min, allowed to stand
for 10 min and then centrifuged for 5 min at
high speed (1000 g). Tumour levels were
determined by preparing a 20% (w/v)
homogenate of tumour in distilled water,
and adding a 0 4 ml aliquot of homogenate
to 2-6 ml absolute ethanol as described above.
The recovery of drug added to plasma or
tumour samples was 90-100%.
In experiments to measure the half-life
and principal metabolites of MIS in control,
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sham-operated and kidney-ligated mice, the
concentrations of 2-nitroimidazoles were de-
termined by the second method: reversed-
phase high-performance liquid chromoto-
graphy (HPLC). At appropriate times after
MIS administration, serial blood samples
were taken from the tail of the same mouse.
Duplicate 5 /A samples were collected in
Microcap pipettes (Drummond Scientific
Company), mixed with 45 ,ul water and stored
at -20°C. Finally (usually at 10-12-5 h)
the mice were bled by cardiac puncture and
the undiluted heparinized whole blood was
stored at -20°C. Blood samples wereanalysed
for MIS and Ro-05-9963 as described pre-
viously for plasma (Workman et al., 1978a).
Concentrations in whole blood were identical
to those in plasma.
Chromatograms of blood samples from
kidney-ligated animals exhibited larger peaks
at the solvent front than those from control
and sham-operated mice. MIS is excreted
in mouse urine partly as glucuronidase-
hydrolysable conjugate(s) of the parent drug
(Flockhart et al., 1978c). We therefore
reasoned that some of the material eluting
at the solvent front might include such polar
conjugates. To test this, samples of 10-12 5 h
whole blood were inicubated in the dark at
37°C with an equal volume of Glucurase
(Sigma Chemical Company). (Glucurase is a
solution of bovine liver ,B-glucuronidase
buffered at pH 5; activity=5000 Sigmaunits/
ml.) Aliquots were removed at 24 h and 48 h
and analysed by HPLC. This treatment
caused a decrease in the peak at the solvent
front and a concomitant increase in the
amount of MIS and Ro-05-9963. These
changes were complete by 24 h. The treat-
ment did not alter the amount of MIS and
Ro-05-9963 in whole blood from control and
sham-operated mice. The difference in con-
centration between digested and undigested
whole blood gave the amount of glucuroni-
dase-hydrolysable conjugates of MIS and
Ro-05-9963. In accordance with previous
convention (Flockhart et al., 1978c), we shall
refer to these as the 0-glucuronide conjugates
of MIS and Ro-05-9963.
RESULTS
Acute toxicity of MIS and Ro-05-9963
The values obtained (at Stanford, in
the same experiment on the same batch
of mice) for the LD50/2d (and 95%O con-
fidence intervals) of MIS and Ro-05-9963
were as follows:
(i)
(ii)
MIS: 9-1 (6.5-12-8) mmol/kg or 1833
(1305-2576) mg/kg.
Ro-05-9963: 16-6 (11.8-23.3) mmol/kg
or 3104 (2212-4355) mg/kg.
The lower toxicity of Ro-05-9963 (by a
factor of 17-2.2) has been found by others
(Flockhart et al., 1978b; Stone, personal
communication, 1978). For both drugs the
deaths of the animals were rapid: even
at doses close to the LD50 only an occa-
sional mouse died beyond 5-6 h after
injection. This, and the comatose nature
of the mice, suggest death by a neuro-
logical mechanism.
Drug levels in plasma and tumour
Earlier radiation experiments with
EMT6 tumours showed that low doses
of Ro-05-9963 produced radiosensitization
of the tumours in vivo, but unlike similar
doses of MIS, the drug was not dose-
modifying (Brown et al., 1978). This
suggested that the drug was not penetrat-
ing adequately to all the hypoxic tumour
cells. Further experiments have been
performed with 3 tumours (the EMT6
tumour, the KHT sarcoma and the
RIF-1 sarcoma) and it has been found
that although at injected doses of 935 mg/
kg (5 mmol/kg) Ro-05-9963 is dose-modi-
fying, it never achieved as high a degree
of radiosensitization as MIS at equimolar
injected doses (Brown et al., in prepara-
tion).
Since Ro-05-9963 and MIS have equal
electron affinities, they would be expected
to be equally effective as radiation sensi-
tizers and, in fact, this appears to be the
case in vitro. Adams et al. (1976) reported
that Ro-05-9963 was slightly less effective
than MIS in radiosensitizing V-79 cells,
whereas Flockhart et al. (1968b) found
that Ro-05-9963 was slightly more so.
Thus it appeared that the most likely
explanation ofthe lower radiosensitization
by Ro-05-9963 in vivo would be the lower
tumour concentration. Since we found
maximum tumour radiosensitization at
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TABLE I. Plasma
Drug and(l ose
MIS
1000 mg/kg
(5 mmol/kg)
Ro-05-996:3
935 mg/kg
(5 mmol/kg)
and tumour concentrations (mM)* of misonidazole and Ro-05-9963
30-45 min after injection
Time
after
inj. (mill)
30
30
30
30
MIean + s.e.
37.5
37-5
:37-5
37-5
A/lean + s.e.
45
45
45
45
AMean Xs.e.
30
30
30
30
Mlean±s.e.
37.5
37-5
37-5
37.5
Mean + s.e.
45
45
45
45
Meani+ s.e.
Plasma
conen.
5-3
4-6
5-6
5-7
4-5
2-8
4-6
5.1
4-2+0-.5
4-3
4-5
4-2
2-8
40-L 0 4
14
2-8
2-4
2-6
2-3+0-3
0-88
2-4
2-5
2-4
2-0 + 0-4
1-5
1 5
0-38
1-2
1*2±03
Tumour
conen.
2-5
3 0
2-6
3-3
2-9±0-2
3-1
1-8
3*0
2-4
2-6±0-3
2-7
2-8
2-7
1-5
2 4 0 3
0-77
1.5
1-1
1*4
12+0-2
0 34
2-4
1-7
1-7
1*5 0-4
0-74
0-76
0-25
0 75
0 63.' 0 13
Tumour/
Plasma
0-48
0-65
0 47
0 59
0°55+0°04
0-69
0-66
0-66
0 47
0-62 + 0-05
0-6:3
0-63
0-63
0 55
0-61 0.02
0 55
0 57
0-46
0 53
0.53 --002
0 39
0-66
0-72
0-69±0-12
0 49
0-51
0-66
0-62
0 57±: 0 04
30-45 min means+ s.e.
Tumour/
Tumotur Plasma
2-6+0-2 0-5941-0-02
11 +0 2 0-60---0*05
* Determine(d by spectrophotometric assay.
30 min after injection, and our longest
exposure in radiation experiments was
15 min, we compared the plasma and
tumour concentrations of Ro-05-9963 and
MIS from 30 to 45 min after an i.p.
injection of equimolar injected doses in
equal volumes of physiological saline.
The results (Table I) show that, despite
the inter-animal variation, the mean
tumour concentration of Ro-05-9963 was
less than 5000 of that of MIS over the
period studied. It can also be seen that
this was due entirely to lower plasma levels
of Ro-05-9963, since the tumour/plasma
ratio of concentrations was the same for
each drug.
At least two possibilities exist for the
lower tumour concentrations of Ro-05-
9963. Firstly, Ro-05-9963 is considerably
less lipophilic than MIS (Adams et al.,
1976; Brown et al., 1978) and hence may
not be as able to penetrate the many
lipoid barriers between the injection site
and the nuclei ofthe tumour cells. Alterna-
tively, a more rapid plasma clearance of
Ro-05-9963 (which may itself be related
to the lower lipophilicity) could have
prevented the maximum uptake and re-
tention in the tissues. The importance of
deciding between these alternative hypo-
theses is that if inadequate absorption
and distribution due to the lower lipo-
philicity were responsible for the lower
tumour concentrations of Ro-05-9963,
this property of the drug would be likely
to apply both in man and mouse. However,
if the lower tumour concentrations were
due to the rapid clearance of Ro-05-9963
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in the mouse, this might not be a problem
in man, where the plasma half-life of
MIS is considerably longer than in the
mouse and might also be true for Ro-05-
9963.
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FIG. 1. The plasma concentration of MIS
(0) after an injection of 5 mmol/kg and
of Ro-05-9963 (0) after an injection of
10 mmol/kg, as a function oftime after i.p.
injection into (Stanford) female BALB/c
mice (±s.e.). The data vere obtained by
the UV spectrophotometric method on
blood obtained on killing 4 mice at each
interval. The half-lives and 950 confidlence
intervals were calculated by least-squares
regression analysis.
Fig. 1 shows plasma levels as a ftinction
of time after injection in the same experi-
ment, of doses of MIS and Ro-05-9963
designed to give the same initial plasma
levels in BALB/c mice. (The importance
of comparing plasma clearance half-lives
of two drugs at the same peak level stems
from the observation by ourselves and
others (Brown, unpublished; Workman
et al., in preparation; Chin et al., 1978):
that the half-life is significantly longer
with higher initial concentrations. This
might be due to hypothermia and reduced
metabolic rate at high drug doses, or it
might be a corollary of an elimination rate
with saturable kinetics.) It can be seen
that despite equal peak plasma levels the
plasma half-life was less for Ro-05-9963
(33 min) than for MIS (94 min). These data
also confirm the conclusion from the
previous experiment, that the peakplasma
concentration of Ro-05-9963 is -50%
of that for equimolar injected doses of
MIS. However, the Ro-05-9963 data
extrapolate to a zero time value on the
concentration axis which is twice that for
MIS, which suggests the same apparent
volume of distribution (Vd) for the two
drugs. Estimates of Vd should, however,
be treated with extreme caution when
drugs are not administered by the i.v.
route.
This demonstration of the shorter
plasma half-life of Ro-05-9963, however,
does not allow us to decide between the
alternative hypotheses posed above for
the lower tumour concentrations of Ro-
05-9963. To do this it was necessary to
prolong the plasma half-lives of the two
drugs, and then observe the effect on the
tumour concentrations. This was done by
preventing all urinary excretion for a few
hours by surgically tying off both kidneys
before drug injection.
Prolongation of drug half-live8
Mice with bilateral nephrectomies, or
with both kidneys ligated, will survive
-48 h. For at least the first 8 h after the
mice recover from the anaesthetic they
do not appear grossly different in be-
haviour or activity from control mice
or from mice given a sham operation.
Thus, to test the hypothesis that the
lower tumour concentrations of Ro-05-
9963 might be due to more rapid clearance
of drug from the plasma, normal mice
and mice with both kidneys ligated
("nephrectomized") were injected within
3 h with equimolar doses of MIS or
Ro-05-9963.
Table II shows plasma and tumour
levels of MIS and Ro-05-9963 at 38 min
and 6 h after injection. From these data
the following conclusions can be drawn:
(i) Plasma and tumour levels of Ro-05-
9963 38 min after injection of normal
mice are less than 50% of those of
MIS, despite equimolar injected doses
(confirming the data in Table I).
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TABLE II.-Effect ofbilateral kidney ligation (BKL) onplasma and tumour concentrations
(mM)* of misonidazole and Ro-05-9963
38 min after injection
BKL Plasma Tumour Tumour/Plasma
5*3 3-4 0-64
4-6 3-5 0-76
4-1 0-5 0-12
4-7 6-4 1-36
4-2 3-4 0-81
49 3-6 0-73
Mean 4-6 3-5 0-74
s.e. 0-2 0-8 0-16
5.7 2-0 0-35
3.4 3.3 0-97
7-0 4-2 0-60
5.5 3-2 0-58
5-3 3-6 0-68
5-9 3-2 0-54
Mean 5-5 3.3 0-62
s.e. 0-5 0-3 0-08
6 h after injection
Plasma Tumour Tumour/Plasma
0-41 0-48 1-17
0-64 0-55 0-86
1-01 0-61 0-60
0-26 0-24 0-92
0-50 0-27 0-54
0-41 0-21 0-51
0-54 0-39 0-77
0-11 0-07 0-11
5-2 4-3 0-83
5-2 3-4 0-65
5-0 2-6 0-52
4.9 2-8 0-57
5-1 2-7 0-53
5-2 3-2 0-62
5.1 3-2 0-62
0-1 0-3 0-05
0-42
0-51
1-93
2-16
2-36
1-27
Mean 1-4
s.e. 0-3
4.7 4.7 5.4
5-1
5-1
4-9
Mean 5-0
s.e. 0.1
0-24
0-25
2-35
1-30
1-58
0-90
1-1
0-3
4-0
3-1 4.3
2-4
2-8
1-6
3-0
0-4
0-57
0-49
1-22
0-60
0-67
0-71
0-71
0-11
0-85
0-66
0-80
0-47
0-55
0 33
0-61
0-08
<0-05
<0-05
<0-05
<0-05
<0-05
<0-05
<0-05
<0-05
<0-05 <0-05
5.9
4-1
4-6
4-7
2-1
3-7
2-3
2-9
0-36
0-90
0-50
0-62
4-8 2-8 0-60
0-4 0-4 011
* Concentrations determined by spectrophotometric assay.
(ii) In kidney-ligated mice there is little
or no decrease in the total 2-nitro-
imidazole concentration in plasma
and tumour up to 6 h after injection.
This indicates that the loss of 2-
nitroimidazoles from the plasma is
more dependent on urinary excretion
than on any other routes of elimina-
tion, including extra-renal meta-
bolism. We cannot, of course, exclude
the kidney as a site of drug meta-
bolism.
(iii) Bilateral kidney ligation increases
the concentration of Ro-05-9963 in
the tumour and plasma, at both 38
min and 6 h, to the same level as MIS.
On the other hand, there is little or
no change in MIS levels in the kidney-
ligated mice at 38 min.
(iv) Bilateral kidney ligation, despite
greatly prolonging the half-lives ofthe
two drugs, does not change the
tumour/plasma ratios, and as in
unligated mice, the tumour/plasma
ratio is the same for MIS and Ro-
05-9963 (60-70%).
In order to characterize more fully the
effect of bilateral kidney ligation on the
pharmacokinetics of MIS, we injected a
dose of 1000 mg/kg (5 mmol/kg) i.p. into
normal, kidney-ligated, or sham-operated
mice. Blood samples were collected from
the mice for up to 12 h after injection and
Drug and dose
MIS
1000 mg/kg
(5 mmol/kg)
No
Ye
Ro-05-9963
935 mg/kg
(5 mmol/kg)
No
Yes
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FIG. 2.-(A) The whole blood concentration (±s.e.) of MIS after an i.p. injection of 5 mmol/kg into
(Cambridge) female BALB/c mice which were either untreated (0), sham-operated (W2), or had
both kidneys ligated (A) before injection. The inverted symbol with (+G) above the point at 12j h
shows the addition of MIS glucuronide to the MIS level. (B) The concentration of Ro-05-9963
(±s.e.) in whole blood of the same mice as in (A). The mice were either untreated (@), sham-
operated (E), or had bilateral kidney ligation (-) before MIS injection. The inverted symbol (V)
shows the addition of Ro-05-9963 glucuronide. Both sets of data were obtained using HPLC on
successive blood samples from 5 mice per treatment group.
0-1
0:1
TIME AFTER LP INJECTION (h)
FIG. 3.-The concentration of MIS+Ro-05-
9963 (±s.e.) in the blood of mice as a
function of time after a single injection
of 5 mmol/kg (1000 mg/kg) of MIS. The
mice were either untreated (0), sham-
operated (O) or had both kidneys ligated
(A) before injection. These data sum the
corresponding data in Fig. 2.
assayed for MIS and its 0-demethylated
metabolite Ro-05-9963, using HPLC. In
addition, the samples taken at 12 h
were treated with 3-glucuronidase, as
described in the Materials and Methods
section, to determine the levels of MIS
and Ro-05-9963 glucuronides.
TABLE III.-Half-lives (in h with 95% con-
fidence limits)* for total non-conjugated
2-nitroimidazole (MIS+Ro-05-9963)t in
normal and kidney-ligated mice
Control
3.5 (3.2-3 9)
2-6 (2-5-2-7)
2-6 (2.3 3-0)
2-0 (1-8-2-2)
2-1 (1.9-2.3)
Sham-operated
2-3 (2-1-2-5)
2-9 (2.7-3.2)
3-6 (3.3-4.0)
2.6 (2.3-3.0)
2-5 (1-9-3-3) 2-8 (2-1-3.8)
2-6 (2-2-3-1)
Kidney-ligated
9-6 (8-2-11.5)
8-8 (6-6-13-0)
11-9 (10-8-13-3)
10-3 (9.1 11.9)
11-3 (10.0-13.0)
10-3 (8-8-12-0)
*Determined using least-squares regression on the
data 1-9 h after injection.
tConcentrations measured by HPLC.
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Figs. 2 and 3 and Table III show the
results. There was a clear difference
between the half-lives of MIS (Fig. 2A)
and of MIS +Ro-05-9963 (Fig. 3) in the
kidney-ligated mice and in control or
sham-operated mice. As can be seen from
Table III, there was no significant differ-
ence between the half-lives in the control
and sham-operated mice (the higher drug
concentrations at each sampling time in
the sham-operated mice over those in the
controls (Figs. 2 and 3) are not significant,
but, if real, could be the result of the
anaesthetic or operation trauma).
The levels ofthe metabolite Ro-05-9963
build up considerably in the "nephrectom-
ized" mice, to reach a steady-state con-
centration of about 0O8 mm, with no
indication of any decrease at 12-5 h (Fig.
2B). In contrast, steady-state plasma
concentrations in normal and sham-
operated mice were about 027 mm for
up to 6 h, before declining rapidly. How-
ever, the relative proportions of Ro-05-
9963 to total non-conjugated 2-nitro-
imidazoles (MIS+Ro-05-9963) were not
significantly different at any time in
control and nephrectomized mice, rising
from 5% at 38 min after injection in
both groups to 24% in the normal and
22% in the nephrectomized mice by
6-5 h.
As well as detecting the Ro-05-9963
metabolite, we also observed the
glucuronide conjugates of both MIS and
Ro-05-9963 in the plasma of nephrectom-
ized mice (Figs. 2 and 3) at levels which
were .30%O of total 2-nitroimidazoles.
These conjugates were not found in the
plasma of normal and sham-operated
mice.
As a further test of the comparability
of the kidney-ligated and normal mice,
we measured rectal temperatures at hourly
intervals after MIS injection. During the
first 5 h after injection all 3 groups had
an identical temperature drop (5.0°C)
due to the MIS injection. However, by
9 h after injection the rectal temperature
of the controls had risen to within 30C
of uninjected mice, whereas the kidney-
ligated mice had fallen still further to
7°C below the uninjected level.
The effect of prolonged half-lives on radio-
sensitization
In order to determine whether bilateral
kidney ligation would overcome the lower
drug levels of Ro-05-9963 in the hypoxic,
radioresistant tumour cells, a radiation
experiment was made to compare the
radiosensitization produced as a function
of time after an injection of 2-5 mmol/kg
of Ro-05-9963 or MIS into normal and
bilaterally kidney-ligated mice. The results
are shown in Table IV. As predicted from
TABLE IV.-Effect of kidney ligation on
radiosensitization of hypoxic tumour cells
by Ro-05-9963
Drug
and
dose
Saline
MIS
2-5 mmol/kg
Ro-05-9963
2 5 mmol/kg
Surviving
fraction
Kidney after
ligation 1750 rad1
No 2-5 x 10-2
Yes 3-7 x 10-2
No 1-91 x 10-3
(1.61-2-26)
No 3-15 x 10-3
(2-34-4.23)
Yes 1-47 x 10-3
(1.14-1.89)
Survival
ratio2
0-062
0-102
P=
0-047J
-0-05
1Mean of values at 15, 30, 45 and 60 min after
drug injection (with s.e. limits).
2Ratio ofSurviving fraction in drug-injected mice
Surviving fraction in saline-injected mice
the tumour concentrations, the extent of
radiosensitization was less for Ro-05-9963
than for MIS at equimolar injected doses
in the untreated mice, but was the same
as (or slightly greater than) that for MIS
when the blood flow to both kidneys was
occluded before injection of Ro-05-9963.
DISCUSSION
These data show that after equimolar
injected doses of Ro-05-9963 and MIS,
the plasma and tumour concentrations
of Ro-05-9963 are less than those of MIS
by a factor of 2 or more. In other experi-
ments it was shown that this lower tumour
concentration is responsible for the lower
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radiosensitization produced by Ro-05-9963
(Brown et al., in preparation). It was
further shown that the lower tumour
concentration ofRo-05-9963 was notdueto
inadequate absorption or distribution
resulting from its lower lipophilicity, but
was due to the short plasma half-life of
the drug. When all urinary excretion
of the drugs was prevented, and plasma
levels remained constant for an hour or
more, no differences between the tumour
concentrations in the MIS and Ro-05-9963
injected mice were seen.
The significance of this lies in the fact
that in man the relatively long plasma
half-life of MIS almost certainly contri-
butes to the drug's toxicity (Saunders
et al., 1978). Thus, a valid direction in
drug design would be to decrease the half-
life without losing the high plasma and
tumour levels achievable with MIS. Since
the half-life in man is -12 h (Foster et al.,
1975; Dische et al., 1977; Wiltshire et al.,
1978; Workman et al., 1978b), it should
be possible to reduce this by a factor of
4 or 5 without changing peak tumour
levels. However, in testing such drugs in
the mouse or rat, such a reduction in the
plasma half-life could result (as it does
with Ro-05-9963) in low plasma and
tumour concentrations. This could lead to
rejection of the drug if a radiation assay
alone were used to screen the efficacy of
new compounds. Thus, it is necessary to
determine tumour levels of the various
drugs in conjunction with radiation
assays.
However, although necessary, the deter-
mination of tumour levels of new drugs
as a function of injected dose will not be
sufficient to extrapolate their usefulness
from mice to man. A relatively low tumour
concentration, with or without low plasma
levels, could be due either to very rapid
clearance from the blood (as with Ro-05-
9963), or it could be due to inadequate
penetration of the drug through the
various lipoid membranes between the
site of application and the tumour cells.
In the former caseit would not be expected
in man, because of the relatively long
half-life, but in the latter case a similar
problem could be expected in man.
The technique of bilateral kidney liga-
tion may help to resolve the problem.
This procedure prolongs the plasma half-
life of MIS in the mouse from -2 h to
10 h, similar to that in man. It remains
to be seen whether this will applygenerally
to other 2-nitroimidazole radiosensitizers,
but it is promising that the conclusions
reached using bilateral kidney ligation
in comparing Ro-05-9963 andMIS (namely
that the lower plasma concentrations of
Ro-05-9963 than MIS found in the mouse
will not apply in man) are borne out in
the dog, which has a plasma half-life
intermediate between nmouse and man
(White and Workman, in preparation).
Of course, kidney ligation produces an
increasingly abnormal physiological state
which could influence drug pharmaco-
kinetics. For example, in man uraemia
due to impaired renal function can some-
times shorten and sometimes prolong
the apparent half-life of drugs eliminated
partly by metabolism (Reidenberg, 1974,
1977). Kidney ligation also precludes any
metabolism of the drugs by the kidney.
However, since we found the ratio of
Ro-05-9963 to unchanged MIS in the
plasma of kidney-ligated mice to be the
same as that in control mice, this possi-
bility is probably not relevant in the
present case.
The second question posed in the
introductory section was to what extent
does the plasma half-life affect thetumour/
plasma ratio of drug concentrations? We
conclude that, for the two drugs studied
and at the injected doses (5 mmol/kg),
a change in plasma half-life from --30 min
to 10 h does not influence the tumour/
plasma ratio. Thus, in Tables I and II
it can be seen that at all times after
injection of either MIS or Ro-05-9963,
in either normal or kidney-ligated mice,
the ratio of nitroimidazole in the tumour
to that in plasma is 60-70%. This con-
clusion is contrary both to the generally
held view (e.g. Adams, 1977; Dische et al.,
1977; Stratford & Adams, 1978; Dene-
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kamp & Fowler, 1978) and to the inference
of McNally et al. (1978) that the longer
half-life of MIS in man than in mice
would result in a higher human tumour/
plasma ratio. Their data, however, do not
support this suggestion; they found in
different mouse tumours concentrations
18-72% of that in blood, compared to a
range of 42-107% of plasma levels in
human tumours (Gray et al., 1976; Dische
et al., 1977; Urtasun et al., 1977). Further,
more recent clinical studies, using HPLC
analysis, have shown that after the
administration of MIS the concentrations
of the parent drug and the metabolite
Ro-05-9963 were normally in the range
50-70% of the corresponding plasma
concentrations (Wiltshire et al., 1978;
Workman et al., 1978b). Thus there seems
little evidence that the tumour/plasma
ratio in man is generally higher than in
the mouse; in both species the ratio may
be a function of the individual tumour
rather than of the drug's plasma half-life.
The present studies have clearly shown
that tumour levels ofMIS and Ro-05-9963
maintain a constant ratio to plasma
concentration, but are -,.30-40% lower.
It is therefore of interest to ask why the
concentrations in tumour and plasma are
not equal. There appear to be two possi-
bilities:
(i) The partitioning of the 2-nitroimi-
dazoles from plasma to tumour is not
equal.
(ii) The partitioning is equal, but the
nitroimidazoles are metabolized in
the tumour.
Data are available in support of both
hypotheses. In support of the metabolism
hypothesis, Varghese et al. (1976) and
Flockhart et al. (1978a) have provided
evidence that reduction of the nitro group
in mouse tumours in vivo depends upon
the particular tumour type.
In support of the partitioning hypo-
thesis, the data of Flockhart et al. (1978c)
have shown that the uptake of (2-14C)
MIS by the MT mouse tumour and some
normal mouse tissues was less than 100%
of the plasma concentration, particularly
at less than 6 h after injection. In contrast,
concentrations in liver were considerably
higher than in plasma. Also pertinent
is the recent finding that the saliva/plasma
ratio for MIS in man was less than unity
(0 87i0 05) (Workman et al., 1978b).
The extent oftumour necrosis may have
an important influence on the uptake and
metabolism of 2-nitroimidazoles. In man
the reported concentration of MIS in
necrotic fluid varies widely (Flockhart
et al., 1978a). Rauth et al. (1978) have
shown that the concentration of MIS in
the necrotic fluid of the KHT mouse
tumour can be considerably lower than
that in the whole tumour. The Stanford
EMT6 tumour used in the present study
contained a large necrotic centre occupy-
ing roughly 30% of the tumour volume
(Brown et al., 1978). The Cambridge
EMT6 tumour is rather less necrotic, but
necrosis increases with tumour size, and
it is relevant that MIS concentrations are
considerably lower in 300mm3 tumours
than in 100mm3 ones (Workman et al.,
in preparation).
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